Dr. Shah on Status of CAR T-cell Therapies in ALL

Video

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

The first FDA approval will likely be in pediatric ALL, Shah says. However, in the adult patients with ALL, researchers are closely behind.

However, several pharmaceutical companies have been entering the space and are actively conducting clinical trials with these agents. These therapies have the ability to produce durable remissions and improve survival, Shah says.

Related Videos
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Holly Peay, PhD, senior research scientist at RTI International
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
Holly Peay, PhD, senior research scientist at RTI International
Terence R. Flotte, MD, the vice president of ASGCT and the provost and executive deputy chancellor of UMass Chan Medical School
Deepak L. Bhatt, MD, MPH, MBA
Jeffrey Chamberlain, PhD, on Bringing Back the Focus to Basic Research for ASGCT 2024
Amit Soni, MD, the Center for Inherited Blood Disorders
Jonathan W. Weinsaft, MD, Future Research With Gene Therapy for Cardiovascular Disease
Related Content
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Evaluating Autologous Cord Blood Derived Cells for the Treatment of Preterm Infants

April 8th 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed his lab’s research in the field of neonatal cell therapy.

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Standardized Guidelines for Preclinical Testing and Cell Characterization are Critical to Cell Therapy Development

April 3rd 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed the importance of preclinical guidelines in the context of neonatal cell therapy.

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

March 4th 2022
Article

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

June 27th 2021
Article

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

June 9th 2021
Article

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

© 2024 MJH Life Sciences

All rights reserved.